AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
XOANACYL is an oral therapy designed to address critical challenges in CKD,…
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025 16:01 ET Â | Source: Nurix Therapeutics, Inc. SAN FRANCISCO,…
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025 09:00 ET Â | Source: RAPT Therapeutics, Inc. SOUTH SAN…
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 10, 2025 13:33 ET Â | Source: MiNK Therapeutics NEW YORK, June…
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
June 06, 2025 16:01 ET Â | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer…
Addex Convenes Annual General Meeting 2025
June 03, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…